Prostate Cancer Therapeutics Market- Global Industrial Analysis and Forecast (2023-2029)

Prostate Cancer Therapeutics Market was valued at US$ 13.11 Bn in 2022 and is expected to reach US$ 21.51 Bn by 2029, at a CAGR of 7.33 % during a forecast period. The objective of the report is to present a comprehensive assessment of the market and contains thoughtful insights, facts, historical data, industry-validated market data and projections with a suitable set of assumptions and methodology. The report also helps in understanding prostate cancer therapeutics market dynamics, structure by identifying and analyzing the market segments and project the global market size. Further, report also focus on competitive analysis of key players by product, price, financial position, product portfolio, growth strategies and regional presence. To know about the Research Methodology :- Request Free Sample Report The report also provide PEST analysis, PORTER’s analysis, SWOT analysis to address question of shareholders to prioritizing the efforts and investment in near future to emerging segment in prostate cancer therapeutics market.The report study has analyzed revenue impact of COVID -19 pandemic on the sales revenue of market leaders, market followers and market disrupters in the report and same is reflected in our analysis. The prostate is an exocrine gland found in men, placed within the groin space just under the bladder and before of the body part. In prostate cancer, cells inside the gland mutate change into cancer cells. Additional, these affected cells begin killing the opposite healthy gland cells, and might unfold to the opposite body parts. Prostate cancer is that the second leading reason for new cancer cases in men globally and therefore the sixth leading cause for cancerous death in men. Innovations within the development of recent drugs and therapies, sizable amount of recent drugs stepping into the market with FDA approval, high growth in hormone-refractory glandular cancer medicine market, and rise in base of aging population are key driving factors for the expansion of this market. Additionally, rise in prevalence of glandular cancer, dynamic fashion habits of populations, increased patient’s attention awareness, and increasing demand for non-invasive therapies are expected to push the market growth in the forecast period. Alongside these driving factors, the marketplace for prostate cancer is facing some challenges like time overwhelming regulative compliance and high price of prostate drugs. However, the marketplace for prostate cancer is probably going to rise in the forecast period because of the large number of current innovations for the treatment of prostate cancer. Based on Product Type, Hormone therapy, among product type segments in the prostate cancer therapeutics is highly attractive and is likely to stay this way in the forecast period and is expected to remain dominant throughout the forecast timeframe. Hormonal therapy is also called as androgen deprivation therapy (ADT). The hormone therapy helps to reduce the level of androgens that are male hormones which fuel the growth of cancer. Suppressing the hormone level, the drugs help to decrease the growth of cancer of prostate. The immunotherapy drugs for prostate cancer are projected to register the highest CAGR globally. In terms of end-user, they are segregated as hospital pharmacy, retail pharmacy, and online pharmacy. The hospital pharmacy accounted for the largest share in the global prostate cancer therapeutics market in 2021. The growing number of the patient pool for medical care in hospitals is the leading factor contributing towards the high share of segment in the global market. Geographically, North America holds major share in the prostate cancer therapeutics market due to high number of prostate cancer patients whereas APAC and South America are likely to be grow moderately in the prostate cancer therapeutics market due to rising awareness about the disease. Europe is expected to grow at significant rates owing to increase in prevalence rates and developed healthcare infrastructure facilities.

Prostate Cancer Therapeutics Market Scope: Inquire before buying

Global Prostate Cancer Therapeutics Market
Report Coverage Details
Base Year: 2022 Forecast Period: 2023-2029
Historical Data: 2018 to 2022 Market Size in 2023: US$ 13.11Bn.
Forecast Period 2023 to 2029 CAGR: 7.33% Market Size in 2029: US$ 21.51 Bn.
Segments Covered: by Product Type 1.Chemotherapy 1.1.Jevtana 1.2.Mitoxantrone 1.3.Taxotere 1.4.Estramustine 1.5.Others 2.Targeted Therapy 3.Immunotherapy
by End User 1. Hospital Pharmacy 2. Retail Pharmacy 3 .Online Pharmacy

Prostate Cancer Therapeutics Market, by Region:

North America (United States, Canada and Mexico) Europe (UK, France, Germany, Italy, Spain, Sweden, Austria and Rest of Europe) Asia Pacific (China, South Korea, Japan, India, Australia, Indonesia, Malaysia, Vietnam, Taiwan, Bangladesh, Pakistan and Rest of APAC) Middle East and Africa (South Africa, GCC, Egypt, Nigeria and Rest)

Key Players

1. Bristol-Myers Squibb Company 2. EUSA Pharma,Inc. 3. OSI Retail Pharmacy, Inc. 4. Paladin Labs Inc. 5. Amgen Inc. 6. Cell Genesys Inc. 7. Spectrum Retail Pharmacy, Inc. 8. Indevus Retail Pharmacy Inc. 9. Medimmune 10. Dendreon Corporation 11. Genentech Inc. 12. Abbott Laboratories 13. GlaxoSmithKline Plc 14. Pfizer Inc. 15. Immunomedics, Inc. 16. Progenics Retail Pharmacy, Inc. 17. Takeda Pharmaceutical Company Limited 18. Sanofi-Aventis SA 19. F. Hoffmann-La Roche Ltd. 20. Novartis AG 21. ALZA Corporation 22. AstraZeneca PLC Frequently Asked Questions: 1. Which region has the largest share in Global Prostate Cancer Therapeutics Market ? Ans: Asia Pacific region held the highest share in 2022. 2. What is the growth rate of Global Prostate Cancer Therapeutics Market t? Ans: The Global Market is growing at a CAGR of 7.33% during forecasting period 2023-2029. 3. What is scope of the Global Prostate Cancer Therapeutics Market report? Ans: Global Market report helps with the PESTEL, PORTER, COVID-19 Impact analysis, Recommendations for Investors & Leaders, and market estimation of the forecast period. 4. What is the study period of this Market? Ans: The Global  Market is studied from 2022 to 2029.

Global Prostate Cancer Therapeutics Market

1. Preface 1.1. Report Scope and Market Segmentation 1.2. Research Highlights 1.3. Research Objectives 2. Assumptions and Research Methodology 2.1. Report Assumptions 2.2. Abbreviations 2.3. Research Methodology 2.3.1. Secondary Research 2.3.1.1. Secondary data 2.3.1.2. Secondary Function 2.3.2. Primary Research 2.3.2.1. Data from Primary Function 2.3.2.2. Breakdown of Primary Function 3. Executive Summary: Global Prostate Cancer Therapeutics Size, by Market Value (US$ Bn) and Market Volume (Units) 4. Market Overview 4.1. Introduction 4.2. Market Indicator 4.2.1. Drivers 4.2.2. Restraints 4.2.3. Opportunities 4.2.4. Challenges 4.3. Porter’s Analysis 4.4. Value Chain Analysis 4.5. Market Risk Analysis 4.6. SWOT Analysis 4.7. Industry Trends and Emerging Technologies 4.8. Patent Registration 5. Supply Side and Demand Side Indicators 6. Global Prostate Cancer Therapeutics Market Analysis and Forecast 6.1. Global Prostate Cancer Therapeutics Market Size & Y-o-Y Growth Analysis 6.1.1. North America 6.1.2. Europe 6.1.3. Asia Pacific 6.1.4. Middle East & Africa 6.1.5. South America 7. Global Prostate Cancer Therapeutics Market Analysis and Forecast, by Product Type 7.1. Introduction and Definition 7.2. Key Findings 7.3. Global Prostate Cancer Therapeutics Market Value Share Analysis, by Product Type 7.4. Global Prostate Cancer Therapeutics Market Size (US$ Bn) Forecast, by Product Type 7.5. Global Prostate Cancer Therapeutics Market Analysis, by Product Type 7.6. Global Prostate Cancer Therapeutics Market Attractiveness Analysis, by Product Type 8. Global Prostate Cancer Therapeutics Market Analysis and Forecast, by End user 8.1. Introduction and Definition 8.2. Key Findings 8.3. Global Prostate Cancer Therapeutics Market Value Share Analysis, by End user 8.4. Global Prostate Cancer Therapeutics Market Size (US$ Bn) Forecast, by End user 8.5. Global Prostate Cancer Therapeutics Market Analysis, by End user 8.6. Global Prostate Cancer Therapeutics Market Attractiveness Analysis, by End user 9. Global Prostate Cancer Therapeutics Market Analysis, by Region 9.1. Global Prostate Cancer Therapeutics Market Value Share Analysis, by Region 9.2. Global Prostate Cancer Therapeutics Market Size (US$ Bn) Forecast, by Region 9.3. Global Prostate Cancer Therapeutics Market Attractiveness Analysis, by Region 10. North America Prostate Cancer Therapeutics Market Analysis 10.1. Key Findings 10.2. North America Prostate Cancer Therapeutics Market Overview 10.3. North America Prostate Cancer Therapeutics Market Value Share Analysis, by Product Type 10.4. North America Prostate Cancer Therapeutics Market Forecast, by Product Type 10.4.1. Hormonal Therapy 10.4.1.1. Luteinizing Hormone-releasing Hormone (LHRH) Analogs 10.4.1.2. Luteinizing Hormone-releasing Hormone (LHRH) Antagonists 10.4.1.3. Anti-androgens 10.4.2. Chemotherapy 10.4.2.1. Jevtana 10.4.2.2. Mitoxantrone 10.4.2.3. Taxotere 10.4.2.4. Estramustine 10.4.2.5. Others 10.4.3. Targeted Therapy 10.4.4. Immunotherapy 10.5. North America Prostate Cancer Therapeutics Market Value Share Analysis, by End user 10.6. North America Prostate Cancer Therapeutics Market Forecast, by End user 10.6.1. Hospital Pharmacy 10.6.2. Retail Pharmacy 10.6.3. Online Pharmacy 10.7. North America Prostate Cancer Therapeutics Market Value Share Analysis, by Country 10.8. North America Prostate Cancer Therapeutics Market Forecast, by Country 10.8.1. U.S. 10.8.2. Canada 10.9. North America Prostate Cancer Therapeutics Market Analysis, by Country 10.10. U.S. Prostate Cancer Therapeutics Market Forecast, by Product Type 10.10.1. Hormonal Therapy 10.10.1.1. Luteinizing Hormone-releasing Hormone (LHRH) Analogs 10.10.1.2. Luteinizing Hormone-releasing Hormone (LHRH) Antagonists 10.10.1.3. Anti-androgens 10.10.2. Chemotherapy 10.10.2.1. Jevtana 10.10.2.2. Mitoxantrone 10.10.2.3. Taxotere 10.10.2.4. Estramustine 10.10.2.5. Others 10.10.3. Targeted Therapy 10.10.4. Immunotherapy 10.11. U.S. Prostate Cancer Therapeutics Market Forecast, by End user 10.11.1. Hospital Pharmacy 10.11.2. Retail Pharmacy 10.11.3. Online Pharmacy 10.12. Canada Prostate Cancer Therapeutics Market Forecast, by Product Type 10.12.1. Hormonal Therapy 10.12.1.1. Luteinizing Hormone-releasing Hormone (LHRH) Analogs 10.12.1.2. Luteinizing Hormone-releasing Hormone (LHRH) Antagonists 10.12.1.3. Anti-androgens 10.12.2. Chemotherapy 10.12.2.1. Jevtana 10.12.2.2. Mitoxantrone 10.12.2.3. Taxotere 10.12.2.4. Estramustine 10.12.2.5. Others 10.12.3. Targeted Therapy 10.12.4. Immunotherapy 10.13. Canada Prostate Cancer Therapeutics Market Forecast, by End user 10.13.1. Hospital Pharmacy 10.13.2. Retail Pharmacy 10.13.3. Online Pharmacy 10.14. North America Prostate Cancer Therapeutics Market Attractiveness Analysis 10.14.1. By Product Type 10.14.2. By End user 10.15. PEST Analysis 10.16. Key Trends 10.17. Key Developments 11. Europe Prostate Cancer Therapeutics Market Analysis 11.1. Key Findings 11.2. Europe Prostate Cancer Therapeutics Market Overview 11.3. Europe Prostate Cancer Therapeutics Market Value Share Analysis, by Product Type 11.4. Europe Prostate Cancer Therapeutics Market Forecast, by Product Type 11.4.1. Hormonal Therapy 11.4.1.1. Luteinizing Hormone-releasing Hormone (LHRH) Analogs 11.4.1.2. Luteinizing Hormone-releasing Hormone (LHRH) Antagonists 11.4.1.3. Anti-androgens 11.4.2. Chemotherapy 11.4.2.1. Jevtana 11.4.2.2. Mitoxantrone 11.4.2.3. Taxotere 11.4.2.4. Estramustine 11.4.2.5. Others 11.4.3. Targeted Therapy 11.4.4. Immunotherapy 11.5. Europe Prostate Cancer Therapeutics Market Value Share Analysis, by End user 11.6. Europe Prostate Cancer Therapeutics Market Forecast, by End user 11.6.1. Hospital Pharmacy 11.6.2. Retail Pharmacy 11.6.3. Online Pharmacy 11.7. Europe Prostate Cancer Therapeutics Market Value Share Analysis, by Country 11.8. Europe Prostate Cancer Therapeutics Market Forecast, by Country 11.8.1. Germany 11.8.2. U.K. 11.8.3. France 11.8.4. Italy 11.8.5. Spain 11.8.6. Rest of Europe 11.9. Europe Prostate Cancer Therapeutics Market Analysis, by Country 11.10. Germany Prostate Cancer Therapeutics Market Forecast, by Product Type 11.10.1. Hormonal Therapy 11.10.1.1. Luteinizing Hormone-releasing Hormone (LHRH) Analogs 11.10.1.2. Luteinizing Hormone-releasing Hormone (LHRH) Antagonists 11.10.1.3. Anti-androgens 11.10.2. Chemotherapy 11.10.2.1. Jevtana 11.10.2.2. Mitoxantrone 11.10.2.3. Taxotere 11.10.2.4. Estramustine 11.10.2.5. Others 11.10.3. Targeted Therapy 11.10.4. Immunotherapy 11.11. Germany Prostate Cancer Therapeutics Market Forecast, by End user 11.11.1. Hospital Pharmacy 11.11.2. Retail Pharmacy 11.11.3. Online Pharmacy 11.12. U.K. Prostate Cancer Therapeutics Market Forecast, by Product Type 11.12.1. Hormonal Therapy 11.12.1.1. Luteinizing Hormone-releasing Hormone (LHRH) Analogs 11.12.1.2. Luteinizing Hormone-releasing Hormone (LHRH) Antagonists 11.12.1.3. Anti-androgens 11.12.2. Chemotherapy 11.12.2.1. Jevtana 11.12.2.2. Mitoxantrone 11.12.2.3. Taxotere 11.12.2.4. Estramustine 11.12.2.5. Others 11.12.3. Targeted Therapy 11.12.4. Immunotherapy 11.13. U.K. Prostate Cancer Therapeutics Market Forecast, by End user 11.13.1. Hospital Pharmacy 11.13.2. Retail Pharmacy 11.13.3. Online Pharmacy 11.14. France Prostate Cancer Therapeutics Market Forecast, by Product Type 11.14.1. Hormonal Therapy 11.14.1.1. Luteinizing Hormone-releasing Hormone (LHRH) Analogs 11.14.1.2. Luteinizing Hormone-releasing Hormone (LHRH) Antagonists 11.14.1.3. Anti-androgens 11.14.2. Chemotherapy 11.14.2.1. Jevtana 11.14.2.2. Mitoxantrone 11.14.2.3. Taxotere 11.14.2.4. Estramustine 11.14.2.5. Others 11.14.3. Targeted Therapy 11.14.4. Immunotherapy 11.15. France Prostate Cancer Therapeutics Market Forecast, by End user 11.15.1. Hospital Pharmacy 11.15.2. Retail Pharmacy 11.15.3. Online Pharmacy 11.16. Italy Prostate Cancer Therapeutics Market Forecast, by Product Type 11.16.1. Hormonal Therapy 11.16.1.1. Luteinizing Hormone-releasing Hormone (LHRH) Analogs 11.16.1.2. Luteinizing Hormone-releasing Hormone (LHRH) Antagonists 11.16.1.3. Anti-androgens 11.16.2. Chemotherapy 11.16.2.1. Jevtana 11.16.2.2. Mitoxantrone 11.16.2.3. Taxotere 11.16.2.4. Estramustine 11.16.2.5. Others 11.16.3. Targeted Therapy 11.16.4. Immunotherapy 11.17. Italy Prostate Cancer Therapeutics Market Forecast, by End user 11.17.1. Hospital Pharmacy 11.17.2. Retail Pharmacy 11.17.3. Online Pharmacy 11.18. Spain Prostate Cancer Therapeutics Market Forecast, by Product Type 11.18.1. Hormonal Therapy 11.18.1.1. Luteinizing Hormone-releasing Hormone (LHRH) Analogs 11.18.1.2. Luteinizing Hormone-releasing Hormone (LHRH) Antagonists 11.18.1.3. Anti-androgens 11.18.2. Chemotherapy 11.18.2.1. Jevtana 11.18.2.2. Mitoxantrone 11.18.2.3. Taxotere 11.18.2.4. Estramustine 11.18.2.5. Others 11.18.3. Targeted Therapy 11.18.4. Immunotherapy 11.19. Spain Prostate Cancer Therapeutics Market Forecast, by End user 11.19.1. Hospital Pharmacy 11.19.2. Retail Pharmacy 11.19.3. Online Pharmacy 11.20. Rest of Europe Prostate Cancer Therapeutics Market Forecast, by Product Type 11.20.1. Hormonal Therapy 11.20.1.1. Luteinizing Hormone-releasing Hormone (LHRH) Analogs 11.20.1.2. Luteinizing Hormone-releasing Hormone (LHRH) Antagonists 11.20.1.3. Anti-androgens 11.20.2. Chemotherapy 11.20.2.1. Jevtana 11.20.2.2. Mitoxantrone 11.20.2.3. Taxotere 11.20.2.4. Estramustine 11.20.2.5. Others 11.20.3. Targeted Therapy 11.20.4. Immunotherapy 11.21. Rest of Europe Prostate Cancer Therapeutics Market Forecast, by End user 11.21.1. Hospital Pharmacy 11.21.2. Retail Pharmacy 11.21.3. Online Pharmacy 11.22. Europe Prostate Cancer Therapeutics Market Attractiveness Analysis 11.22.1. By Product Type 11.22.2. By End user 11.23. PEST Analysis 11.24. Key Trends 11.25. Key Developments 12. Asia Pacific Prostate Cancer Therapeutics Market Analysis 12.1. Key Findings 12.2. Asia Pacific Prostate Cancer Therapeutics Market Overview 12.3. Asia Pacific Prostate Cancer Therapeutics Market Value Share Analysis, by Product Type 12.4. Asia Pacific Prostate Cancer Therapeutics Market Forecast, by Product Type 12.4.1. Hormonal Therapy 12.4.1.1. Luteinizing Hormone-releasing Hormone (LHRH) Analogs 12.4.1.2. Luteinizing Hormone-releasing Hormone (LHRH) Antagonists 12.4.1.3. Anti-androgens 12.4.2. Chemotherapy 12.4.2.1. Jevtana 12.4.2.2. Mitoxantrone 12.4.2.3. Taxotere 12.4.2.4. Estramustine 12.4.2.5. Others 12.4.3. Targeted Therapy 12.4.4. Immunotherapy 12.5. Asia Pacific Prostate Cancer Therapeutics Market Value Share Analysis, by End user 12.6. Asia Pacific Prostate Cancer Therapeutics Market Forecast, by End user 12.6.1. Hospital Pharmacy 12.6.2. Retail Pharmacy 12.6.3. Online Pharmacy 12.7. Asia Pacific Prostate Cancer Therapeutics Market Value Share Analysis, by Country 12.8. Asia Pacific Prostate Cancer Therapeutics Market Forecast, by Country 12.8.1. China 12.8.2. India 12.8.3. Japan 12.8.4. ASEAN 12.8.5. Rest of Asia Pacific 12.9. Asia Pacific Prostate Cancer Therapeutics Market Analysis, by Country 12.10. China Prostate Cancer Therapeutics market forecast, by Product Type 12.10.1. Hormonal Therapy 12.10.1.1. Luteinizing Hormone-releasing Hormone (LHRH) Analogs 12.10.1.2. Luteinizing Hormone-releasing Hormone (LHRH) Antagonists 12.10.1.3. Anti-androgens 12.10.2. Chemotherapy 12.10.2.1. Jevtana 12.10.2.2. Mitoxantrone 12.10.2.3. Taxotere 12.10.2.4. Estramustine 12.10.2.5. Others 12.10.3. Targeted Therapy 12.10.4. Immunotherapy 12.11. China Prostate Cancer Therapeutics Market Forecast, by End user 12.11.1. Hospital Pharmacy 12.11.2. Retail Pharmacy 12.11.3. Online Pharmacy 12.12. India Prostate Cancer Therapeutics Market Forecast, by Product Type 12.12.1. Hormonal Therapy 12.12.1.1. Luteinizing Hormone-releasing Hormone (LHRH) Analogs 12.12.1.2. Luteinizing Hormone-releasing Hormone (LHRH) Antagonists 12.12.1.3. Anti-androgens 12.12.2. Chemotherapy 12.12.2.1. Jevtana 12.12.2.2. Mitoxantrone 12.12.2.3. Taxotere 12.12.2.4. Estramustine 12.12.2.5. Others 12.12.3. Targeted Therapy 12.12.4. Immunotherapy 12.13. India Prostate Cancer Therapeutics Market Forecast, by End user 12.13.1. Hospital Pharmacy 12.13.2. Retail Pharmacy 12.13.3. Online Pharmacy 12.14. Japan Prostate Cancer Therapeutics Market Forecast, by Product Type 12.14.1. Hormonal Therapy 12.14.1.1. Luteinizing Hormone-releasing Hormone (LHRH) Analogs 12.14.1.2. Luteinizing Hormone-releasing Hormone (LHRH) Antagonists 12.14.1.3. Anti-androgens 12.14.2. Chemotherapy 12.14.2.1. Jevtana 12.14.2.2. Mitoxantrone 12.14.2.3. Taxotere 12.14.2.4. Estramustine 12.14.2.5. Others 12.14.3. Targeted Therapy 12.14.4. Immunotherapy 12.15. Japan Prostate Cancer Therapeutics Market Forecast, by End user 12.15.1. Hospital Pharmacy 12.15.2. Retail Pharmacy 12.15.3. Online Pharmacy 12.16. ASEAN Prostate Cancer Therapeutics Market Forecast, by Product Type 12.16.1. Hormonal Therapy 12.16.1.1. Luteinizing Hormone-releasing Hormone (LHRH) Analogs 12.16.1.2. Luteinizing Hormone-releasing Hormone (LHRH) Antagonists 12.16.1.3. Anti-androgens 12.16.2. Chemotherapy 12.16.2.1. Jevtana 12.16.2.2. Mitoxantrone 12.16.2.3. Taxotere 12.16.2.4. Estramustine 12.16.2.5. Others 12.16.3. Targeted Therapy 12.16.4. Immunotherapy 12.17. ASEAN Prostate Cancer Therapeutics Market Forecast, by End user 12.17.1. Hospital Pharmacy 12.17.2. Retail Pharmacy 12.17.3. Online Pharmacy 12.18. Rest of Asia Pacific Prostate Cancer Therapeutics Market Forecast, by Product Type 12.18.1. Hormonal Therapy 12.18.1.1. Luteinizing Hormone-releasing Hormone (LHRH) Analogs 12.18.1.2. Luteinizing Hormone-releasing Hormone (LHRH) Antagonists 12.18.1.3. Anti-androgens 12.18.2. Chemotherapy 12.18.2.1. Jevtana 12.18.2.2. Mitoxantrone 12.18.2.3. Taxotere 12.18.2.4. Estramustine 12.18.2.5. Others 12.18.3. Targeted Therapy 12.18.4. Immunotherapy 12.19. Rest of Asia Pacific Prostate Cancer Therapeutics Market Forecast, by End user 12.19.1. Hospital Pharmacy 12.19.2. Retail Pharmacy 12.19.3. Online Pharmacy 12.20. Asia Pacific Prostate Cancer Therapeutics Market Attractiveness Analysis 12.20.1. By Product Type 12.20.2. By End user 12.21. PEST Analysis 12.22. Key Trends 12.23. Key Developments 13. Middle East & Africa Prostate Cancer Therapeutics Market Analysis 13.1. Key Findings 13.2. Middle East & Africa Prostate Cancer Therapeutics Market Overview 13.3. Middle East & Africa Prostate Cancer Therapeutics Market Value Share Analysis, by Product Type 13.4. Middle East & Africa Prostate Cancer Therapeutics Market Forecast, by Product Type 13.4.1. Hormonal Therapy 13.4.1.1. Luteinizing Hormone-releasing Hormone (LHRH) Analogs 13.4.1.2. Luteinizing Hormone-releasing Hormone (LHRH) Antagonists 13.4.1.3. Anti-androgens 13.4.2. Chemotherapy 13.4.2.1. Jevtana 13.4.2.2. Mitoxantrone 13.4.2.3. Taxotere 13.4.2.4. Estramustine 13.4.2.5. Others 13.4.3. Targeted Therapy 13.4.4. Immunotherapy 13.5. Middle East & Africa Prostate Cancer Therapeutics Market Value Share Analysis, by End user 13.6. Middle East & Africa Prostate Cancer Therapeutics Market Forecast, by End user 13.6.1. Hospital Pharmacy 13.6.2. Retail Pharmacy 13.6.3. Online Pharmacy 13.7. Middle East & Africa Prostate Cancer Therapeutics Market Value Share Analysis, by Country 13.8. Middle East & Africa Prostate Cancer Therapeutics Market Forecast, by Country 13.8.1. GCC 13.8.2. South Africa 13.8.3. Rest of Middle East & Africa 13.9. Middle East & Africa Prostate Cancer Therapeutics Market Analysis, by Country 13.10. GCC Prostate Cancer Therapeutics Market Forecast, by Product Type 13.10.1. Hormonal Therapy 13.10.1.1. Luteinizing Hormone-releasing Hormone (LHRH) Analogs 13.10.1.2. Luteinizing Hormone-releasing Hormone (LHRH) Antagonists 13.10.1.3. Anti-androgens 13.10.2. Chemotherapy 13.10.2.1. Jevtana 13.10.2.2. Mitoxantrone 13.10.2.3. Taxotere 13.10.2.4. Estramustine 13.10.2.5. Others 13.10.3. Targeted Therapy 13.10.4. Immunotherapy 13.11. GCC Prostate Cancer Therapeutics Market Forecast, by End user 13.11.1. Hospital Pharmacy 13.11.2. Retail Pharmacy 13.11.3. Online Pharmacy 13.12. South Africa Prostate Cancer Therapeutics Market Forecast, by Product Type 13.12.1. Hormonal Therapy 13.12.1.1. Luteinizing Hormone-releasing Hormone (LHRH) Analogs 13.12.1.2. Luteinizing Hormone-releasing Hormone (LHRH) Antagonists 13.12.1.3. Anti-androgens 13.12.2. Chemotherapy 13.12.2.1. Jevtana 13.12.2.2. Mitoxantrone 13.12.2.3. Taxotere 13.12.2.4. Estramustine 13.12.2.5. Others 13.12.3. Targeted Therapy 13.12.4. Immunotherapy 13.13. South Africa Prostate Cancer Therapeutics Market Forecast, by End user 13.13.1. Hospital Pharmacy 13.13.2. Retail Pharmacy 13.13.3. Online Pharmacy 13.14. Rest of Middle East & Africa Prostate Cancer Therapeutics Market Forecast, by Product Type 13.14.1. Hormonal Therapy 13.14.1.1. Luteinizing Hormone-releasing Hormone (LHRH) Analogs 13.14.1.2. Luteinizing Hormone-releasing Hormone (LHRH) Antagonists 13.14.1.3. Anti-androgens 13.14.2. Chemotherapy 13.14.2.1. Jevtana 13.14.2.2. Mitoxantrone 13.14.2.3. Taxotere 13.14.2.4. Estramustine 13.14.2.5. Others 13.14.3. Targeted Therapy 13.14.4. Immunotherapy 13.15. Rest of Middle East & Africa Prostate Cancer Therapeutics Market Forecast, by End user 13.15.1. Hospital Pharmacy 13.15.2. Retail Pharmacy 13.15.3. Online Pharmacy 13.16. Middle East & Africa Prostate Cancer Therapeutics Market Attractiveness Analysis 13.16.1. By Product Type 13.16.2. By End user 13.17. PEST Analysis 13.18. Key Trends 13.19. Key Developments 14. South America Prostate Cancer Therapeutics Market Analysis 14.1. Key Findings 14.2. South America Prostate Cancer Therapeutics Market Overview 14.3. South America Prostate Cancer Therapeutics Market Value Share Analysis, by Product Type 14.4. South America Prostate Cancer Therapeutics Market Forecast, by Product Type 14.4.1. Hormonal Therapy 14.4.1.1. Luteinizing Hormone-releasing Hormone (LHRH) Analogs 14.4.1.2. Luteinizing Hormone-releasing Hormone (LHRH) Antagonists 14.4.1.3. Anti-androgens 14.4.2. Chemotherapy 14.4.2.1. Jevtana 14.4.2.2. Mitoxantrone 14.4.2.3. Taxotere 14.4.2.4. Estramustine 14.4.2.5. Others 14.4.3. Targeted Therapy 14.4.4. Immunotherapy 14.5. South America Prostate Cancer Therapeutics Market Value Share Analysis, by End user 14.6. South America Prostate Cancer Therapeutics Market Forecast, by End user 14.6.1. Hospital Pharmacy 14.6.2. Retail Pharmacy 14.6.3. Online Pharmacy 14.7. South America Prostate Cancer Therapeutics Market Value Share Analysis, by Country 14.8. South America Prostate Cancer Therapeutics Market Forecast, by Country 14.8.1. Brazil 14.8.2. Mexico 14.8.3. Rest of South America 14.9. South America Prostate Cancer Therapeutics Market Analysis, by Country 14.10. Brazil Prostate Cancer Therapeutics Market Forecast, by Product Type 14.10.1. Hormonal Therapy 14.10.1.1. Luteinizing Hormone-releasing Hormone (LHRH) Analogs 14.10.1.2. Luteinizing Hormone-releasing Hormone (LHRH) Antagonists 14.10.1.3. Anti-androgens 14.10.2. Chemotherapy 14.10.2.1. Jevtana 14.10.2.2. Mitoxantrone 14.10.2.3. Taxotere 14.10.2.4. Estramustine 14.10.2.5. Others 14.10.3. Targeted Therapy 14.10.4. Immunotherapy 14.11. Brazil Prostate Cancer Therapeutics Market Forecast, by End user 14.11.1. Hospital Pharmacy 14.11.2. Retail Pharmacy 14.11.3. Online Pharmacy 14.12. Mexico Prostate Cancer Therapeutics Market Forecast, by Product Type 14.12.1. Hormonal Therapy 14.12.1.1. Luteinizing Hormone-releasing Hormone (LHRH) Analogs 14.12.1.2. Luteinizing Hormone-releasing Hormone (LHRH) Antagonists 14.12.1.3. Anti-androgens 14.12.2. Chemotherapy 14.12.2.1. Jevtana 14.12.2.2. Mitoxantrone 14.12.2.3. Taxotere 14.12.2.4. Estramustine 14.12.2.5. Others 14.12.3. Targeted Therapy 14.12.4. Immunotherapy 14.13. Mexico Prostate Cancer Therapeutics Market Forecast, by End user 14.13.1. Hospital Pharmacy 14.13.2. Retail Pharmacy 14.13.3. Online Pharmacy 14.14. Rest of South America Prostate Cancer Therapeutics Market Forecast, by Product Type 14.14.1. Hormonal Therapy 14.14.1.1. Luteinizing Hormone-releasing Hormone (LHRH) Analogs 14.14.1.2. Luteinizing Hormone-releasing Hormone (LHRH) Antagonists 14.14.1.3. Anti-androgens 14.14.2. Chemotherapy 14.14.2.1. Jevtana 14.14.2.2. Mitoxantrone 14.14.2.3. Taxotere 14.14.2.4. Estramustine 14.14.2.5. Others 14.14.3. Targeted Therapy 14.14.4. Immunotherapy 14.15. Rest of South America Prostate Cancer Therapeutics Market Forecast, by End user 14.15.1. Hospital Pharmacy 14.15.2. Retail Pharmacy 14.15.3. Online Pharmacy 14.16. South America Prostate Cancer Therapeutics Market Attractiveness Analysis 14.16.1. By Product Type 14.16.2. By End user 14.17. PEST Analysis 14.18. Key Trends 14.19. Key Developments 15. Company Profiles 15.1. Market Share Analysis, by Company 15.2. Competition Matrix 15.2.1. Competitive Benchmarking of key players by price, presence, market share, End users and R&D investment 15.2.2. New Product Launches and Product Enhancements 15.2.3. Market Consolidation 15.2.3.1. M&A by Regions, Investment and End users 15.2.3.2. M&A Key Players, Forward Integration and Backward Integration 15.3. Company Profiles: Key Players 15.3.1. Bristol-Myers Squibb Company 15.3.1.1. Company Overview 15.3.1.2. Financial Overview 15.3.1.3. Product Portfolio 15.3.1.4. Business Strategy 15.3.1.5. Recent Developments 15.3.1.6. Manufacturing Footprints 15.3.2. EUSA Pharma, Inc. 15.3.3. OSI Retail Pharmacy, Inc. 15.3.4. Paladin Labs Inc. 15.3.5. Amgen Inc. 15.3.6. Cell Genesys Inc. 15.3.7. Spectrum Retail Pharmacy, Inc. 15.3.8. Indevus Retail Pharmacy Inc. 15.3.9. Medimmune 15.3.10. Dendreon Corporation 15.3.11. Genentech Inc. 15.3.12. Abbott Laboratories 15.3.13. GlaxoSmithKline Plc 15.3.14. Pfizer Inc. 15.3.15. Immunomedics, Inc. 15.3.16. Progenics Retail Pharmacy, Inc. 15.3.17. Takeda Pharmaceutical Company Limited 15.3.18. Sanofi-Aventis SA 15.3.19. F. Hoffmann-La Roche Ltd. 15.3.20. Novartis AG 15.3.21. ALZA Corporation 15.3.22. AstraZeneca PLC 16. Primary Key Insights
  • INQUIRE BEFORE BUYING